Home › Non-Small Cell Lung Cancer › Washington › Tacoma
Non-Small Cell Lung Cancer clinical trials in Tacoma, WA
20 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Tacoma (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Northwest Medical Specialties Tacoma /ID# 270534, Tacoma
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RecruitingPhase 1/2
- Northwest Medical Specialties Tacoma /ID# 270469, Tacoma
- Vista Oncology - East Olympia /ID# 275438, Olympia · 26 mi away
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RecruitingPhase 3
- Northwest Medical Specialties - Tacoma, Tacoma
- Northwest Medical Specialties - Gig Harbor, Gig Harbor · 8 mi away
- Northwest Medical Specialties - Puyallup Medical Oncology, Puyallup · 8 mi away
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- American Oncology Network Vista Oncology Division-West office, Olympia · 26 mi away
- American Oncology Network Vista Oncology Division-East office, Olympia · 26 mi away
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RecruitingPhase 3
- Vista Oncology Inc PS, Olympia · 26 mi away
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Vista Oncology, Olympia · 26 mi away
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RecruitingPhase 3
- American Oncology Network Vista Oncology Division-West office, Olympia · 26 mi away
- American Oncology Network Vista Oncology Division-East office, Olympia · 26 mi away
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
- Northwest Medical Specialties, Tacoma
Pan-tumor MRD Study
RecruitingObservational study
- Northwest Medical Specialties (NWMS), Tacoma
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Tacoma
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RecruitingPhase 3
- Local Institution - 0499, Lacey · 23 mi away
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Research Site, Tacoma
- Research Site, Olympia · 26 mi away
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2/3
- Vista Oncology - East Olympia /ID# 262303, Olympia · 26 mi away
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Tacoma
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RecruitingPhase 1
- Northwest Medical Specialties, Tacoma
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
RecruitingPhase 3
- Research Site, Tacoma
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- Exigent Research, LLC, Tacoma
- Northwest Medical Specialities, PLLC, Tacoma
- Northwest Medical Specialities. PLLC, Gig Harbor · 8 mi away
- and 3 more
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecruitingPhase 3
- MultiCare Institute for Research & Innovation, Tacoma
- MultiCare Regional Cancer Center, Gig Harbor · 8 mi away
- MultiCare Regional Cancer Center, Puyallup · 8 mi away
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RecruitingPhase 2
- USA09-0, Puyallup · 8 mi away
BostonGene and Exigent Genomic INsight Study
RecruitingObservational study
- Northwest Medical Specialities, Puyallup · 8 mi away
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Tacoma
- Breast Cancer18 studies
- Ulcerative Colitis15 studies
- Multiple Myeloma13 studies
- Prostate Cancer11 studies
- Crohn's Disease11 studies
- Colorectal Cancer9 studies
- Metastatic Cancer9 studies
- Melanoma7 studies
- Ovarian Cancer7 studies
- Stomach Cancer6 studies
- Esophageal Cancer6 studies
- Cancer (all types)6 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.